Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments

Neuroscience and Biobehavioral Reviews

Volumn 75, Issue , 2017, Pages 157-165

  Renard, Justine ^a   Norris, Christopher ^a   Rushlow, Walter ^a   Laviolette, Steven R ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Cannabidiol; Dopamine; Pharmacotherapy; Post traumatic stress disorder; Schizophrenia

Indexed keywords

CANNABIDIOL; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; SEROTONIN 5A RECEPTOR; DRONABINOL;

COGNITIVE DEFECT; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; HUMAN; MENTAL INSTABILITY; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROMODULATION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; UPREGULATION;

CANNABIDIOL; DOPAMINE; DRONABINOL; HUMANS; SCHIZOPHRENIA;

EID: 85012066454     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2017.02.006     Document Type: Review

References (79)

1. Alimohamad, H., Sutton, L., Mouyal, J., Rajakumar, N., Rushlow, W.J., The effects of antipsychotics on B-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem. 95 (2005), 513–525.
2. Andréasson, S., Allebeck, P., Engström, A., Rydberg, U., Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 26 (1987), 1483–1486.
3. Asad Khan, A., Antonio, M., Pepio, A.M., Sossin, W.S., Serotonin activates S6 kinase in a rapamycin-sensitive manner in Aplysia synaptosomes. J. Neurosci. 21:2 (2001), 382–391.
4. Awad, A.G., Voruganti, L.N.P., Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 (2004), 877–893.
5. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A.E., Martín-Santos, R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36 (2011), 1219–1226.
6. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’ Carroll, C.M., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., McGuire, P.K., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 (2010), 764–774.
7. Bhattacharyya, S., Crippa, J.A., Allen, P., Martin-Santos, R., Borgwardt, S., Fusar-Poli, P., Rubia, K., Kambeitz, J., O'Carroll, C., Seal, M.L., Giampietro, V., Brammer, M., Zuardi, A.W., Atakan, Z., McGuire, P.K., Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 69 (2012), 27–36.
8. Bhattacharyya, S., Atakan, Z., Martin-Santos, R., Crippa, J.A., Kambeitz, J., Prata, D., Williams, S., Brammer, M., Collier, D.A., McGuire, P.K., Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Mol. Psychiatry 17 (2012), 1152–1155.
9. Bloom, A.S., Johnson, K.M., Dewey, W.L., The effects of cannabinoids on body temperature and brain catecholamine synthesis. Res. Commun. Chem. Pathol. Pharmacol. 20 (1978), 51–57.
10. Bloomfield, M.A., Morgan, C.J., Kapur, S., Curran, H.V., Howes, O.D., The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology 231 (2014), 2251–2259.
11. Bloomfield, M.A., Morgan, C.J., Egerton, A., Kapur, S., Curran, H.V., Howes, O.D., Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 75 (2014), 470–478.
12. Bossong, M.G., Niesink, J.M., Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 92 (2010), 370–385.
13. Bossong, M.G., Mehta, M.A., van Berckel, B.N., Howes, O.D., Kahn, R.S., Stokes, P.R., Further human evidence for striatal dopamine release induced by administration of Δ9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 232 (2015), 2723–2729.
14. Bruijnzeel, D., Tandon, R., Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression. Drug Des. Dev. Ther. 10 (2016), 1641–1647.
15. 1A receptors. J. Psychiatr. Res. 46 (2012), 1501–1510.
16. Chadwick, B., Miller, M.L., Hurd, Y.L., Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry, 4, 2013, 129.
17. Cheer, J.F., Wassum, K.M., Heien, M.L., Phillips, P.E., Wightman, R.M., Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 24 (2004), 4393–4400.
18. Citrome, L., Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc) 51 (2015), 397–414.
19. Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simões, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M.C., McGuire, P.K., Zuardi, A.W., Busatto, G.F., Hallak, J.E., Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25 (2011), 121–130.
20. D'souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch An Brayley, G., Gueorguiva, R., Cooper, T.B., Krystal, J.H., Delta-9-Tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. Biol. Psychiatry 57 (2005), 594–608.
21. Dalton, V.S., Long, L.E., Weickert, C.S., Zavitsanou, K., Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36 (2011), 1620–1630.
22. Dean, B., Sundram, S., Bradbury, R., Scarr, E., Copolov, D., Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103 (2001), 9–15.
23. Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T.R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S.A., Wiffen, B., Powell, J., Murray, R.M., High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 195 (2009), 488–491.
24. Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238.
25. Dinieri, J.A., Hurd, Y.L., Rat models of prenatal and adolescent cannabis exposure. Methods Mol. Biol. 829 (2012), 231–242.
26. Draycott, B., Loureiro, M., Ahmad, T., Tan, H., Zunder, J., Laviolette, S.R., Cannabinoid transmission in the prefrontal cortex Bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. J. Neurosci. 34 (2014), 13096–13109.
27. Emamian, E.S., AKT/GSK3 signaling pathway and schizophrenia. Front. Mol. Neurosci., 15(5), 2012, 33.
28. 1A receptors and previous stressful experience. Eur. Neuropsychopharm. 24 (2014), 410–419.
29. Freyberg, Z., Ferrando, S.J., Javitch, J.A., Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry 167 (2010), 388–396.
30. Fujita, S., Kiguchi, M., Lee, J., Terakado, M., Suga, K., Hatanaka, H., Koshikawa, N., 5-HT 1A and 5-HT 1B receptors in the ventrolateral striatum differentially modulate apomorphine-induced jaw movements in rats. J. Oral Sci. 50 (2008), 387–395.
31. Guimarães, V.M., Zuardi, A.W., Del Bel, E.A., Guimarães, F.S., Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 75 (2004), 633–638.
32. Gururajan, A., Van Den Buuse, M., Is the mTOR-signalling cascade disrupted in schizophrenia?. J. Neurochem. 129 (2014), 377–387.
33. Gururajan, A., Taylor, D.A., Malone, D.T., Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia. Behav. Brain Res. 222 (2011), 299–308.
34. Hardwick, S., King, L., Home Office Cannabis Potency Study. 2008, Home Office, U.K.
35. Herrera, A.S., Casanova, J.P., Gatica, R.I., Escobar, F., Fuentealba, J.A., Clozapine pre-treatment has a protracted hypolocomotor effect on the induction and expression of amphetamine sensitization. Prog. Neuropsychopharmacol. Biol. Psychiatry 47 (2013), 1–6.
36. 1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur. J. Pharmacol. 287 (1995), 179–184.
37. Jernigan, C.S., Goswami, D.B., Austin, M.C., Iyo, A.H., Chandran, A., Stockmeier, C.A., Karolewicz, B., The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 1774–1779.
38. 1A receptors mediate inhibition of tyrosine hydroxylation in rat striatum. J. Pharmacol. Exp. Ther. 266 (1993), 133–141.
39. Katsidoni, V., Anagnostou, I., Panagis, G., Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict. Biol. 18 (2013), 286–296.
40. Kozlovsky, N., Shanon-Weickert, C., Tomaskovic-Crook, E., Kleinman, J.E., Belmaker, R.H., Agam, G., Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J. Neural Transm. 111 (2004), 1583–1592.
41. Kuepper, R., Ceccarini, J., Lataster, J., van Os, J., van Kroonenburgh, M., van Gerven, J.M., Marcelis, M., Van Laere, K., Henquet, C., Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS One, 8(7), 2013, e70378.
42. Laviolette, S.R., Grace, A.A., The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell. Mol. Life Sci. 63 (2006), 1597–1613.
43. Leweke, F.M., Giuffrida, A., Koethe, D., Schreiber, D., Nolden, B.M., Kranaster, L., Neatby, M.A., Schneider, M., Gerth, C.W., Hellmich, M., Klosterkötter, J., Piomelli, D., Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94 (2007), 29–36.
44. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter, J., Hellmich, M., Koethe, D., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry, 2, 2012, e94.
45. Liu, Y., Fanburg, B.L., Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am. J. Respir. Cell Mol. Biol. 34 (2006), 182–191.
46. Liu, Y., Pham, X., Zhang, L., Chen, P., Burzynski, G., Mcgaughey, D.M., He, S., Mcgrath, J.A., Wolyniec, P., Fallin, M.D., Pierce, M.S., Mccallion, A.S., Pulver, A.E., Avramopoulos, D., Valle, D., Functional variants in DPYSL2 sequence increase risk of schizophrenia and suggest a link to mTOR signaling. G3 (Bethesda) 5 (2015), 61–72.
47. Long, L.E., Malone, D.T., Taylor, D.A., Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31 (2006), 795–803.
48. Manrique-Garcia, E., Zammit, S., Dalman, C., Hemmingsson, T., Andreasson, S., Allebeck, P., Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol. Med. 42 (2012), 1321–1328.
49. McGrath, J., Saha, S., Chant, D., Welham, J., Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30 (2008), 67–76.
50. Mijangos-Moreno, S., Poot-Aké, A., Arankowsky-Sandoval, G., Murillo-Rodríguez, E., Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats. Neurosci. Res. 84 (2014), 60–63.
51. Moreira, F.A., Guimarães, F.S., Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol. 512 (2005), 199–205.
52. Morgan, C.J., Page, E., Schaefer, C., Chatten, K., Manocha, A., Gulati, S., Curran, H.V., Brandner, B., Leweke, F.M., Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J. Psychiatry 202 (2013), 381–382.
53. Morgan, C.J., Freeman, T.P., Powell, J., Curran, H.V., AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl. Psychiatry, 16(February (6)), 2016, e738, 10.1038/tp.2015.219.
54. Murillo-Rodríguez, E., Palomero-Rivero, M., Millán-Aldaco, D., Mechoulam, R., Drucker-Colín, R., Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci. 88 (2011), 504–511.
55. Norris, C., Loureiro, M., Kramar, C., Zunder, J., Renard, J., Rushlow, W., Laviolette, S.R., Cannabidiol modulates fear memory formation through interactions with serotonergic transmission in the mesolimbic system. Neuropsychopharmacology(June), 2016, 10.1038/npp.2016.93 Epub ahead of print.
56. O'Daly, O.G., Joyce, D., Tracy, D.K., Azim, A., Stephan, K.E., Murray, R.M., Shergill, S.S., Amphetamine sensitization alters reward processing in the human striatum and amygdala. PLoS One, 9(April (4)), 2014, e93955.
57. Pedrazzi, J.F.C., Issy, A.C., Gomes, F.V., Guimarães, F.S., Del-Bel, E.A., Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl.) 232 (2015), 3057–3065.
58. Pertwee, R.G., The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 30 (2006), S13–S18.
59. Poddar, M.K., Dewey, W.L., Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214 (1980), 63–67.
60. Popovic, M., Stanojevic, Z., Tosic, J., Isakovic, A., Paunovic, V., Petricevic, S., Martinovic, T., Ciric, D., Kravic-Stevovic, T., Soskic, V., Kostic-Rajacic, S., Shakib, K., Bumbasirevic, V., Trajkovic, V., Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats. J. Neurochem. 135 (2015), 125–138.
61. Potter, D.J., Clark, P., Brown, M.B., Potency of D9–THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 53 (2008), 90–94.
62. Remington, G., Kapur, S., Antipsychotic dosing: how much but also how often?. Schizophr. Bull. 36 (2010), 900–903.
63. Renard, J., Krebs, M., Le, Pen G., Jay, T.M., Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front. Neurosci. 8 (2014), 1–14.
64. Renard, J., Rushlow, W.J., Laviolette, S.R., What can rats tell us about adolescent cannabis exposure? Insights from preclinical research. Can. J. Psychiatry 61 (2016), 328–334.
65. Renard, J., Rosen, L.G., Loueiro, M., De Oliveira, C., Schmid, S., Rushlow, W.J., Laviolette, S.R., Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex. Cereb. Cortex(January), 2016 E-Pub ahead of print.
66. Renard, J., Rosen, L.G., Loueiro, M., Zunder, J., De Oliveira, C., Schmid, S., Rushlow, W.J., Laviolette, S.R., Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR/p70S6 kinase signaling pathway. J. Neurosci., 4(May), 2016 E-Pub ahead of print.
67. Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005), 1037–1043.
68. Semple, D.M., Mcintosh, A.M., Lawrie, S.M., Cannabis as a risk factor for psychosis: systematic review. J. Psychopharm. 19 (2005), 187–194.
69. Sideli, L., Fisher, H.L., Murray, R.M., Sallis, H., Russo, M., Stilo, S.A., Paparelli, A., Wiffen, B.D., O'Connor, J.A., Pintore, S., Ferraro, L., La Cascia, C., La Barbera, D., Morgan, C., Di Forti, M., Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Early Interv. Psychiatry(November), 2015, 10.1111/eip.12285 Epub ahead of print.
70. Smit, F., Bolier, L., Cuijpers, P., Cannabis use and the risk of later schizophrenia: a review. Addiction 99 (2004), 425–430.
71. Smith, N., High potency cannabis: the forgotten variable. Addiction 100 (2005), 1558–1559.
72. 1A receptors in mice. Behav. Brain Res. 309 (2016), 22–28.
73. Sutton, L.P., Honardoust, D., Mouyal, J., Rajakumar, N., Rushlow, W.J., Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J. Neurochem. 102 (2007), 153–169.
74. Swerdlow, N.R., Light, G.A., Animal models of deficient sensorimotor gating in schizophrenia: are they still relevant?. Curr. Top. Behav. Neurosci.(June), 2016.
75. Tan, H., Ahmad, T., Loureiro, M., Zunder, J., Laviolette, S.R., The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Front Psychiatry, 30(5), 2014, 73.
76. Valvassori, S.S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Chagas, M.H.N., Hallak, J.E.C., Zuardi, A.W., Quevedo, J., Crippa, J.A.S., Effects of cannabidiol on amphetamine-induced oxidative stress generation in an rat model of mania. J. Psychopharmacol. 25 (2011), 274–280.
77. Wu, X., French, E.D., Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39 (2000), 391–398.
78. Zuardi, A.W., Antunes Rodrigues, J., Cunha, J.M., Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.) 104 (1991), 260–264.
79. Zuardi, A.W., Guimarães, F.S., Hallak, J.E., Crippa, J.A., Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?. Expert Rev. Neurother. 11 (2011), 1111–1114.